|
1）Andersson T, Lorentzen B, Hogdahl H, et al. Thrombin-inhibitor complexes in the blood during and after delivery. Thromb Res. 1996; 82(2): 109-17
|
|
|
|
2）Ishii A, Yamada S, Yamada R, et al. t-PA activity in peripheral blood obtained from pregnant women. J Perinat Med. 1994; 22(2): 113-7
|
|
|
|
|
|
3）Lecander I, Astedt B. Isolation of a new specific plasminogen activator inhibitor from pregnancy plasma. Br J Haematol. 1986; 62(2): 221-8
|
|
|
|
|
|
4）Wright JG, Cooper P, Astedt B, et al. Fibrinolysis during normal human pregnancy: complex inter-relationships between plasma levels of tissue plasminogen activator and inhibitors and the euglobulin clot lysis time. Br J Haematol. 1988; 69(2): 253-8
|
|
|
|
|
|
5）Pomp ER, Lenselink AM, Rosendaal FR, et al. Pregnancy, the postpartum period and pro-thrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost. 2008; 6(4): 632-7
|
|
|
|
|
|
6）Heit JA, Kobbervig CE, James AH, et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005; 143(10): 697-706
|
|
|
|
|
|
7）Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost. 1999; 82(2): 610-9
|
|
|
|
|
|
8）Virkus RA, Lokkegaard EC, Bergholt T, et al. Venous thromboembolism in pregnant and puerperal women in Denmark 1995-2005. A national cohort study. Thromb Haemost. 2011; 106(2): 304-9
|
|
|
|
|
|
9）Chan WS, Spencer FA, Ginsberg JS. Anatomic distribution of deep vein thrombosis in preg-nancy. CMAJ. 2010; 182(7): 657-60
|
|
|
|
|
|
10）Gherman RB, Goodwin TM, Leung B, et al. Incidence, clinical characteristics, and timing of objectively diagnosed venous thromboembolism during pregnancy. Obstet Gynecol. 1999; 94(5 Pt 1): 730-4
|
|
|
|
|
|
11）Ray JG, Chan WS. Deep vein thrombosis during pregnancy and the puerperium: a meta-analysis of the period of risk and the leg of presentation. Obstet Gynecol Surv. 1999; 54(4): 265-71
|
|
|
|
|
|
12）Ginsberg JS, Brill-Edwards P, Burrows RF, et al. Venous thrombosis during pregnancy: leg and trimester of presentation. Thromb Haemost. 1992; 67(5): 519-20
|
|
|
|
|
|
13）Lussana F, Coppens M, Cattaneo M, et al. Pregnancy-related venous thromboembolism: risk and the effect of thromboprophylaxis. Thromb Res. 2012; 129(6): 673-80
|
|
|
|
|
|
14）Hayashi T, Nishioka J, Shigekiyo T, et al. Protein S Tokushima: abnormal molecule with a substitution of Glu for Lys-155 in the second epidermal growth factor-like domain of protein S. Blood. 1994; 83(3): 683-90
|
|
|
|
|
|
15）Kimura R, Honda S, Kawasaki T, et al. Protein S-K196E mutation as a genetic risk factor for deep vein thrombosis in Japanese patients. Blood. 2006; 107(4): 1737-8
|
|
|
|
|
|
16）Miyata T, Kimura R, Kokubo Y, et al. Genetic risk factors for deep vein thrombosis among Japanese: importance of protein SK196E mutation. Int J Hematol. 2006; 83(3): 217-23
|
|
|
|
|
17）Shigekiyo T, Uno Y, Kawauchi S, et al. Protein S Tokushima: an abnormal protein S found in a Japanese family with thrombosis. Thromb Haemost. 1993; 70(2): 244-6
|
|
|
|
|
|
18）Gilabert J, Fernandez JA, Espana F, et al. Physiological coagulation inhibitors(protein S, protein C and antithrombin III) in severe preeclamptic states and in users of oral contraceptives. Thromb Res. 1988; 49(3): 319-29
|
|
|
|
|
|
19）Malm J, Laurell M, Dahlback B. Changes in the plasma levels of vitamin K-dependent proteins C and S and of C4b-binding protein during pregnancy and oral contraception. Br J Haematol. 1988; 68(4): 437-43
|
|
|
|
|
|
20）Said JM, Ignjatovic V, Monagle PT, et al. Altered reference ranges for protein C and protein S during early pregnancy: Implications for the diagnosis of protein C and protein S deficiency during pregnancy. Thromb Haemost. 2010; 103(5): 984-8
|
|
|
|
|
|
21）OLeary P, Boyne P, Flett P, et al. Longitudinal assessment of changes in reproductive hormones during normal pregnancy. Clin Chem. 1991; 37(5): 667-72
|
|
|
|
|
|
22）Hughes Q, Watson M, Cole V, et al. Upregulation of protein S by progestins. J Thromb Haemost. 2007; 5(11): 2243-9
|
|
|
|
|
|
23）Suzuki A, Sanda N, Miyawaki Y, et al. Down-regulation of PROS1 gene expression by 17β-estradiol via estrogen receptor alpha (ERα)-Sp1 interaction recruiting receptor-interacting protein 140 and the corepressor-HDAC3 complex. J Biol Chem. 2010; 285(18): 13444-53
|
|
|
|
|
|
24）Gruber CJ, Tschugguel W, Schneeberger C, et al. Production and actions of estrogens. N Engl J Med. 2002; 346(5): 340-52
|
|
|
|
|
|
25）Weihua Z, Andersson S, Cheng G, et al. Update on estrogen signaling. FEBS Lett. 2003; 546(1): 17-24
|
|
|
|
|
|
26）Romeo G, Hughes W, Baker R. Downregulation of protein S by micro-ribonucleic acid 494(mir-494). ISTH2011 Kyoto. 2011; O-MO-017, unpublished data
|
|
|
|
|